'For the first time in Iran we have succeeded in producing edible sustained-release pharmaceuticals,' said Gholam Reza Akhavan Farid, Raha Pharmaceutical Company Managing Director on Saturday.
These products will save Iran from spending $30 million annually, according to Akhavan Farid who manages this knowledge-based company, located in the central Iranian city of Isfahan.
He said his company has sold more than 3.5 million dollars worth of Tegatard® (Carbamazepine 200 mg) and Rahakine® 200 (Sodium valproate) per year, meeting a major part of the country’s internal market. “All the company’s raw materials are produced in Iran,” Raha Pharmaceutical Company managing director stressed.
The pharmaceutical company, founded in 2008, has produced over 120 varieties of finished products such as tablets, capsules, pellets, ampules, eye drops, nasal sprays, syrups and semisolids (creams, gels and ointments) so far.
Sustained-release dosage forms are dosage forms designed to release a drug at a predetermined rate in order to maintain a constant drug concentration for a specific period of time with minimum side effects.
9218**2050
Follow us on Twitter @IrnaEnglish
Tehran, April 20, IRNA - Iran embarked on domestically producing eight sustained-release tablets that are heavily used by epilepsy patients, making the country self-sufficient in meeting a large portion of the internal demand.
